EJCTS Click here for details of sales representative
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wildevuur, C. R.
Right arrow Articles by Ahlvin, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wildevuur, C. R.
Right arrow Articles by Ahlvin, E.

European Journal of Cardio-Thoracic Surgery, Vol 11, 616-623, Copyright © 1997 by European Association for Cardio-thoracic Surgery


ARTICLES

Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European Working Group on heparin coated extracorporeal circulation circuits

CR Wildevuur, PG Jansen, PD Bezemer, DJ Kuik, L Eijsman, P Bruins, AP De Jong, FW Van Hardevelt, JD Biervliet, JM Hasenkam, HH Kure, L Knudsen, L Bellaiche, P Ahlburg, DY Loisance, C Baufreton, P Le Besnerais, G Bajan, A Matta, M Van Dyck, MT Renotte, A Ponlot-Lois, P Baele, EA McGovern and E Ahlvin
Cardio Pulmonary Center Amsterdam, Netherlands.

OBJECTIVES: To evaluate whether the application of heparin treated circuits for elective coronary artery surgery improves postoperative recovery, a European multicenter randomised clinical trial was carried out. METHODS: In 11 European heart centers, 805 low-risk patients underwent cardiopulmonary bypass (CPB) with either an untreated circuit (n = 407) or an identical but heparin treated circuit (n = 398, Duraflo II). RESULTS: Significant differences were found among participating centers with respect to patient characteristics, blood handling procedures and postoperative care. The use of heparin treated circuits revealed no overall changes in blood loss, blood use, time on ventilator, occurrence of adverse events, morbidity, mortality, and intensive care stay. These results did not change after adjustment for centers and (other) prognostic factors as analysed with logistic regression. In both groups no clinical or technical (patient or device related) side effects were reported. Because female gender and aortic cross clamp time appeared as prognostic factors in the logistic regression analysis, a subgroup analysis with these variables was performed. In a subpopulation of females (n = 99), those receiving heparin treated circuits needed less blood products, had a lower incidence of rhythm disturbances and were extubated earlier than controls. In another subgroup of patients with aortic cross clamp time exceeding 60 min (n = 197), the amount of patients requiring prolonged intensive care treatment (> 24 h) was significantly lower when they received heparin treated circuits versus controls. CONCLUSION: These findings suggest that improved recovery can be expected with heparin treated circuits in specific higher risk patient populations (e.g. females) and when prolonged aortic cross clamp time is anticipated. Further investigations are recommended to analyses the clinical benefit of heparin treated circuits in studies with patients in different well defined risk categories and under better standardised circumstances.


This article has been cited by other articles:


Home page
Eur. J. Cardiothorac. Surg.Home page
O. Mangoush
Reply to Ranucci
Eur. J. Cardiothorac. Surg., September 1, 2008; 34(3): 704 - 705.
[Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
M. Ranucci
Clinical impact of heparin-bonded circuits: when a meta-analysis does not clear out the clouds
Eur. J. Cardiothorac. Surg., September 1, 2008; 34(3): 703 - 704.
[Full Text] [PDF]


Home page
Card Surg AdultHome page
J. W. Hammon
Extracorporeal Circulation: Perfusion System
Card. Surg. Adult, January 1, 2008; 3(2008): 350 - 370.
[Full Text]


Home page
Card Surg AdultHome page
J. W. Hammon
Extracorporeal Circulation: The Response of Humoral and Cellular Elements of Blood to Extracorporeal Circulation
Card. Surg. Adult, January 1, 2008; 3(2008): 370 - 389.
[Full Text]


Home page
Eur. J. Cardiothorac. Surg.Home page
O. Mangoush, S. Purkayastha, S. Haj-Yahia, J. Kinross, M. Hayward, F. Bartolozzi, A. Darzi, and T. Athanasiou
Heparin-bonded circuits versus nonheparin-bonded circuits: an evaluation of their effect on clinical outcomes
Eur. J. Cardiothorac. Surg., June 1, 2007; 31(6): 1058 - 1069.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
M. E. Jessen
Pro: Heparin-Coated Circuits Should be Used for Cardiopulmonary Bypass
Anesth. Analg., December 1, 2006; 103(6): 1365 - 1369.
[Full Text] [PDF]


Home page
Anesth. Analg.Home page
R. Taneja and D. C. Cheng
Con: Heparin-Bonded Cardiopulmonary Bypass Circuits Should Be Routine for All Cardiac Surgical Procedures
Anesth. Analg., December 1, 2006; 103(6): 1370 - 1372.
[Full Text] [PDF]


Home page
Asian Cardiovasc. Thorac. Ann.Home page
S. G Raja and G. D Dreyfus
Modulation of Systemic Inflammatory Response after Cardiac Surgery
Asian Cardiovasc Thorac Ann, December 1, 2005; 13(4): 382 - 395.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
R. de Vroege, W. van Oeveren, J. van Klarenbosch, W. Stooker, M. A. J. M. Huybregts, C. E. Hack, L. van Barneveld, L. Eijsman, and C. R. H. Wildevuur
The Impact of Heparin-Coated Cardiopulmonary Bypass Circuits on Pulmonary Function and the Release of Inflammatory Mediators
Anesth. Analg., June 1, 2004; 98(6): 1586 - 1594.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
G. M. Palatianos, C. N. Foroulis, M. I. Vassili, G. Astras, K. Triantafillou, E. Papadakis, A. A. Lidoriki, E. Iliopoulou, and E. N. Melissari
A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit
Ann. Thorac. Surg., July 1, 2003; 76(1): 129 - 135.
[Abstract] [Full Text] [PDF]


Home page
Card Surg AdultHome page
E. A. Hessel II and L. H. Edmunds Jr.
Extracorporeal Circulation: Perfusion Systems
Card. Surg. Adult, January 1, 2003; 2(2003): 317 - 338.
[Full Text]


Home page
Card Surg AdultHome page
P. Menasche and L. H. Edmunds Jr.
Extracorporeal Circulation: The Inflammatory Response
Card. Surg. Adult, January 1, 2003; 2(2003): 349 - 360.
[Full Text]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
F. D. Rubens and T. Mesana
Surface Modified Cardiopulmonary Bypass Circuits: Modifying the Inflammatory Response
Seminars in Cardiothoracic and Vascular Anesthesia, December 1, 2002; 6(4): 301 - 306.
[Abstract] [PDF]


Home page
PerfusionHome page
C. Baufreton, J. L. de Brux, P. Binuani, J.-J. Corbeau, J. B. Subayi, J. C. Daniel, and P. Treanor
A combined approach for improving cardiopulmonary bypass in coronary artery surgery: a pilot study
Perfusion, December 1, 2002; 17(6): 407 - 413.
[Abstract] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. Butler, E. W. Murithi, V. L. Pathi, K. J.D. MacArthur, and G. A. Berg
Duroflo II heparin bonding does not attenuate cytokine release or improve pulmonary function
Ann. Thorac. Surg., July 1, 2002; 74(1): 139 - 142.
[Abstract] [Full Text] [PDF]


Home page
SEMIN CARDIOTHORAC VASC ANESTHHome page
H. A. Hennein
Inflammation After Cardiopulmonary Bypass: Therapy for the Postpump Syndrome
Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2001; 5(3): 236 - 255.
[Abstract] [PDF]


Home page
PerfusionHome page
L.-C. Hsu
Heparin-coated cardiopulmonary bypass circuits: current status
Perfusion, September 1, 2001; 16(5): 417 - 428.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
E. Ovrum, G. Tangen, R. Oystese, M. A. L. Ringdal, and R. Istad
Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations
J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0324 - 330.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
S. Wan, J.-L. LeClerc, M. Antoine, J.-M. DeSmet, A. P.C. Yim, and J.-L. Vincent
Heparin-coated circuits reduce myocardial injury in heart or heart-lung transplantation: a prospective, randomized study
Ann. Thorac. Surg., October 1, 1999; 68(4): 1230 - 1235.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
P. M. McCarthy, J.-P. P. Yared, R. C. Foster, D. A. Ogella, J. A. Borsh, and D. M. Cosgrove III
A prospective randomized trial of Duraflo II heparin-coated circuits in cardiac reoperations
Ann. Thorac. Surg., May 1, 1999; 67(5): 1268 - 1273.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
M. Ranucci, A. Mazzucco, R. Pessotto, G. Grillone, V. Casati, L. Porreca, R. Maugeri, M. Meli, P. Magagna, S. Cirri, et al.
Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial
Ann. Thorac. Surg., April 1, 1999; 67(4): 994 - 1000.
[Abstract] [Full Text] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
V. Videm, T. E. Mollnes, E. Fosse, B. Mohr, MD, K. Bergh, T.-A. Hagve, A. O. Aasen, and J. L. Svennevig
HEPARIN-COATED CARDIOPULMONARY BYPASS EQUIPMENT. I. BIOCOMPATIBILITY MARKERS AND DEVELOPMENT OF COMPLICATIONS IN A HIGH-RISK POPULATION
J. Thorac. Cardiovasc. Surg., April 1, 1999; 117(4): 794 - 802.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 1997 European Association for Cardio-Thoracic Surgery. Published by Elsevier. All rights reserved.